Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.
Karonitsch T, Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, Emery P, Felson D, Gomez-Reino J, Keystone E, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Richards P, van Riel P, Siegel J, Smolen JS, Sokka T, van der Heijde D, van Vollenhoven R, Ward M, Wells G, Zink A, Landewe R. Karonitsch T, et al. Among authors: van der heijde d, van riel p, van vollenhoven r. Ann Rheum Dis. 2008 Oct;67(10):1365-73. doi: 10.1136/ard.2008.092353. Ann Rheum Dis. 2008. PMID: 18791056
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression.
Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF. Rönnelid J, et al. Among authors: van vollenhoven rf. Ann Rheum Dis. 2005 Dec;64(12):1744-9. doi: 10.1136/ard.2004.033571. Epub 2005 Apr 20. Ann Rheum Dis. 2005. PMID: 15843452 Free PMC article.
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Landewé R, et al. Among authors: van der heijde d, van vollenhoven r. Arthritis Rheum. 2006 Oct;54(10):3119-25. doi: 10.1002/art.22143. Arthritis Rheum. 2006. PMID: 17009230 Free article.
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.
Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT; Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Bertsias G, et al. Among authors: van vollenhoven r. Ann Rheum Dis. 2008 Feb;67(2):195-205. doi: 10.1136/ard.2007.070367. Epub 2007 May 15. Ann Rheum Dis. 2008. PMID: 17504841 Free article.
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Keystone E, et al. Among authors: van vollenhoven r. Arthritis Rheum. 2007 Dec;56(12):3896-908. doi: 10.1002/art.23059. Arthritis Rheum. 2007. PMID: 18050221 Free article. Clinical Trial.
512 results